Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose ChemotherapyYuval Shaked, Robert S. Kerbel, Ping Xu et al.|Cancer Research|2016Cited by 58
Bortezomib‐induced pro‐inflammatory macrophages as a potential factor limiting anti‐tumour efficacyOfrat Beyar‐Katz, Yuval Shaked, Valeria Miller et al.|The Journal of Pathology|2016Cited by 25